查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1405884

鐮狀細胞貧血治療市場規模、佔有率、趨勢分析報告：按治療、按最終用途、按地區、細分市場預測，2024-2030 年

Sickle Cell Disease Treatment Market Size, Share & Trends Analysis Report By Treatment (Blood Transfusion, Bone Marrow Transplant), By End-use (Hospitals, Specialty Clinics), By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 120 Pages | 商品交期: 2-10個工作天內

價格

鐮狀細胞貧血治療市場的成長與趨勢：

Grand View Research, Inc.最新報告顯示，到2030年，全球鐮狀細胞疾病治療市場規模預計將達到74.2億美元，預測期內複合年成長率為15.7%。

預計有幾個因素將推動成長，包括增加研發投資、增加目標人口、提高意識計畫以及有利的政府措施。據歐洲鐮狀細胞聯合會稱，歐洲約有 7 萬人患有鐮狀細胞疾病 (SCD)。

引入有助於檢測 SCD 的非侵入性且技術先進的數位技術將有助於克服與靶向鐮狀細胞診斷和治療管理相關的障礙。目前正在開發的 POC 設備是基於光密度測定、側流免疫檢測和微流體電泳等技術。鐮狀細胞疾病診斷率的提高可能會進一步推動成長。

鐮狀細胞疾病的現有治療方法通常可以緩解症狀和安寧療護。這些治療方法通常包括輸血、骨髓移植和藥物治療。然而，骨髓移植是僅推薦給少數患者的唯一可能治癒的治療方法。此外，Global Blood Therapeutics, Inc. 的 Oxbryta、Emmaus Medical, Inc. 的 Endari 和 Agios Pharmaceuticals, Inc. 的 PYRUKYND 等新藥的核准增加預計將推動市場成長。

市場參與者與政府和非政府組織之間加強合作預計將在預測期內推動市場成長。例如，2021 年 2 月，諾華公司與比爾及梅琳達蓋茲基金會合作開發了一種針對鐮狀細胞疾病的新型基因療法。根據協議，比爾及梅琳達蓋茲基金會將提供資金支持開發治療鐮狀細胞疾病的新治療方法。

大量未滿足的醫療需求、強大的管道和不斷增加的患者人數是預期影響市場成長的關鍵因素。近年來，由於缺乏永久治療方法以及與骨髓移植相關的風險，對鐮狀細胞貧血的經濟有效的藥物和基因治療的需求增加。 Bluebird Bio、Bellicum Pharmaceuticals 和 Gamidacell 等公司正積極致力於開發用於治療鐮狀細胞疾病的新型基因療法藥物，預計未來幾年治癒率將會上升。

voxelotor、crizanlizumab、Altemia、rivipansel 等階段研發藥物預計將在預測期內推動鐮狀細胞疾病產業的發展。各國需要在醫療保健方面做出努力，以減輕鐮狀細胞疾病的經濟負擔，改善醫療設施的可近性，並提供早期診斷、後續治療和安寧療護等一系列服務。

鐮狀貧血治療市場報告亮點

  • 根據治療方法，輸血領域在 2023 年佔據市場主導地位。用於管理 SCD 的大量手術和主要治療方案支撐了該細分市場的佔有率。
  • 按最終用途分類，醫院細分市場將在 2023 年佔據最大的市場佔有率，因為醫院已成為治療和診斷這種​​疾病的主要中心。
  • 雖然北美在 2023 年以超過 37.87% 的佔有率主導全球市場，但預計亞太地區在預測期內將以最快的複合年成長率成長。
  • 市場開拓的主要參與者正在採取新產品開發、併購等多種策略，以在預測期內擴大市場佔有率。

目錄

第1章 研究範圍和目的

第 2 章執行摘要

第3章 市場變數、趨勢與範圍

  • 市場體系展望
  • 鐮狀細胞貧血治療的市場動態
    • 市場促進因素分析
    • 市場抑制因素分析
  • 鐮狀細胞貧血治療市場：商業環境分析工具
    • 波特五力分析
    • PESTEL分析
  • 普及和成長前景圖
  • COVID-19感染疾病對鐮狀細胞貧血治療市場的影響

第4章鐮鐮狀細胞性貧血治療市場：治療分析

  • 2018 年和 2030 年鐮狀貧血藥物市場佔有率分析
  • 鐮狀細胞性貧血治療市場：細分儀表板：
  • 2018年至2030年治療細分市場規模、預測、趨勢分析
    • 骨髓移植
    • 輸血
    • 藥物治療

鐮狀鐮狀細胞性貧血治療市場：最終用途分析

  • 2018 年和 2030 年鐮狀細胞貧血症治療最終用途市場佔有率分析
  • 鐮狀細胞貧血症治療最終用途市場：細分儀表板
  • 最終用途細分市場規模、預測、趨勢分析，2018-2030 年
    • 醫院
    • 專科診所
    • 其他

鐮狀鐮狀細胞性貧血治療市場：區域分析

  • 2023 年和 2030 年按地區分類的市場佔有率
  • 北美洲
    • SWOT分析
    • 北美市場，2018-2030
    • 美國
    • 加拿大
  • 歐洲
    • SWOT分析
    • 歐洲市場，2018-2030
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 丹麥
    • 瑞典
    • 挪威
  • 亞太地區
    • SWOT分析
    • 亞太市場，2018-2030
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 泰國
    • 韓國
  • 拉丁美洲
    • SWOT分析
    • 拉丁美洲市場，2018-2030
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中東/非洲
    • SWOT分析
    • MEA鐮狀細胞疾病市場，2018-2030
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第7章競爭分析

  • 公司分類
  • 策略規劃
    • 新產品發布
    • 合夥
    • 獲得
    • 合作
  • 公司簡介
    • Novartis AG
    • Pfizer Inc.
    • bluebird bio, Inc.
    • GlycoMimetics
    • Emmaus Medical, Inc.
    • Bristol-Myers Squibb Company
    • CRISPR Therapeutics
    • Graphite Bio, Inc.
Product Code: GVR-2-68038-442-0

Sickle Cell Disease Treatment Market Growth & Trends:

The global sickle cell disease treatment market size is expected to reach USD 7.42 billion by 2030, registering a CAGR of 15.7% during the forecast period, according to a new report by Grand View Research, Inc. Several factors including increased investments in R&D, a growing target population, increasing awareness programs, and favorable government initiatives are anticipated to drive the growth. According to the European Sickle Cell Federation, around 70 thousand people are living with sickle cell disease (SCD) in Europe.

The introduction of noninvasive, technologically advanced, and digital technologies to facilitate the detection of SCD is set to assist in overcoming the barriers associated with targeted sickle cell diagnosis and treatment management. Presently developed POC devices are based on methodologies such as densitometry, lateral flow immunoassay, and microfluidic electrophoresis. The increase in the diagnosis rate of disease will further facilitate growth.

Available treatments for sickle cell disease usually provide symptomatic relief and palliative care. These treatment methods generally include blood transfusions, bone marrow transplants, and pharmacotherapy. However, a bone marrow transplant is the only potentially curative treatment recommended only to a small percentage of patients. Moreover, increasing approval of novel drugs such as Oxbryta by Global Blood Therapeutics, Inc.;Endari by Emmaus Medical, Inc.; and PYRUKYND by Agios Pharmaceuticals, Inc. is expected to drive the market growth.

Increasing collaborations between market players and government and non-government organizations are anticipated to fuel market growth over the forecast period. For instance, in February 2021, Novartis AG and Bill & Melinda Gates Foundation collaborated to develop novel gene therapy for sickle cell disease. According to the agreement, Bill & Melinda Gates Foundation will provide funding to support the development of novel therapy to cure SKD.

High-unmet medical needs, a strong pipeline, and a growing patient pool are key factors expected to influence market growth. In recent years, demand for cost-effective drugs and gene therapies for sickle cell anemia has increased owing to the unavailability of a permanent cure and the risks associated with bone marrow transplants. Companies such as bluebird bio, Inc.; Bellicum Phamaceuticals, Inc.; and Gamida Cell are actively involved in the development of new effective gene therapies for sickle cell disease treatment, which is expected to increase the treatment rate in the coming years.

Expected launches of late-stage pipeline drugs such as voxelotor, crizanlizumab, Altemia, and rivipansel are projected to drive the sickle cell disease industry during the forecast period. Healthcare initiatives undertaken by respective economies are crucial for curbing the financial burden of the disease as well as for increasing access to healthcare facilities and providing various services for early diagnosis, subsequent treatment, and palliative care.

Sickle Cell Disease Treatment Market Report Highlights:

  • Based on treatment, the blood transfusion segment dominated the market in 2023. The high number of procedures and mostly adopted therapeutic options to manage SCD support the segment share
  • Based on end-use, the hospital segment held the largest market share in 2023 as hospitals served as primary centers for treatment and diagnosis of the disease
  • North America dominated the global market with a share of more than 37.87% in 2023, whereas the Asia Pacific region is projected to grow at the fastest CAGR over the forecast period
  • Key market players are undertaking several strategies such as new product development, mergers & acquisitions to increase their market share over the forecast period.

Table of Contents

Chapter 1 Report Scope and Objectives

  • 1.1 Market Segmentation and Scope
    • 1.1.1 Segment Definitions
      • 1.1.1.1 Treatment segment
      • 1.1.1.2 End-use segment
  • 1.2 Regional Scope
  • 1.3 Estimates and Forecast Timeline
  • 1.4 Objectives
    • 1.4.1 Objective - 1
    • 1.4.2 Objective - 2
    • 1.4.3 Objective - 3
  • 1.5 Research Methodology
  • 1.6 Information Procurement
    • 1.6.1 Purchased Database
    • 1.6.2 GVR's Internal Database
    • 1.6.3 Secondary Sources
    • 1.6.4 Primary research
  • 1.7 Information or Data Analysis
    • 1.7.1 Data Analysis Models
  • 1.8 Market Formulation & Validation
  • 1.9 Model Details
    • 1.9.1 Commodity Flow Analysis
  • 1.10 List of Secondary Sources
  • 1.11 List of Abbreviations

Chapter 2 Executive Summary

  • 2.1 Market Outlook
  • 2.2 Segment Outlook
    • 2.2.1 Treatment
    • 2.2.2 End-use
    • 2.2.3 Region
  • 2.3 Competitive Insights

Chapter 3 Market Variables, Trends & Scope

  • 3.1 Market Lineage Outlook
  • 3.2 Sickle cell disease treatment Market Dynamics
    • 3.2.1 Market Driver Analysis
      • 3.2.1.1 Increasing prevalence of disease
      • 3.2.1.2 Awareness programs and services
      • 3.2.1.3 Presence of reimbursement policies
    • 3.2.2 Market Restraint Analysis
      • 3.2.2.1 Adverse effects and risks related to the treatment procedure
  • 3.3 Sickle cell disease treatment Market: Business Environment Analysis Tools
    • 3.3.1 PORTER'S Five Forces Analysis
      • 3.3.1.1 Threat of new entrants
      • 3.3.1.2 Bargaining power of suppliers
      • 3.3.1.3 Bargaining power of buyers
      • 3.3.1.4 Competitive rivalry
      • 3.3.1.5 Threat of substitutes
    • 3.3.2 PESTEL Analysis
      • 3.3.2.1 Political & Legal
      • 3.3.2.2 Economic & Social
      • 3.3.2.3 Technological
  • 3.4 Penetration & Growth Prospect Mapping
  • 3.5 Impact of COVID-19 on the sickle cell disease treatment market

Chapter 4 Sickle Cell Disease Treatment Market: Treatment Analysis

  • 4.1 Sickle Cell Disease Treatment Treatment Market Share Analysis, 2018 & 2030
  • 4.2 Sickle Cell Disease Treatment Treatment Market: Segment Dashboard:
  • 4.3 Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the Treatment Segment
    • 4.3.1 Bone Marrow Transplant
      • 4.3.1.1 Bone marrow transplant market, 2018 - 2030 (USD Million)
    • 4.3.2 Blood Transfusion
      • 4.3.2.1 Blood transfusion market, 2018 - 2030 (USD Million)
    • 4.3.3 Pharmacotherapy
      • 4.3.3.1 Pharmacotherapy market, 2018 - 2030 (USD Million)

Chapter 5 Sickle Cell Disease Treatment Market: End-use Analysis

  • 5.1 Sickle Cell Disease Treatment End-use Mode Market Share Analysis, 2018 & 2030
  • 5.2 Sickle Cell Disease Treatment End-use Mode Market: Segment Dashboard
  • 5.3 Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the End-use Mode Segment
    • 5.3.1 Hospitals
      • 5.3.1.1 Hospitals market, 2018 - 2030 (USD Million)
    • 5.3.2 Specialty Clinics
      • 5.3.2.1 Specialty Clinics market, 2018 - 2030 (USD Million)
    • 5.3.3 Others
      • 5.3.3.1 Others market, 2018 - 2030 (USD Million)

Chapter 6 Sickle Cell Disease Treatment Market: Regional Analysis

  • 6.1. Sickle Cell Disease Market Share By Region, 2023 & 2030
  • 6.2. North America
    • 6.2.1. SWOT Analysis
    • 6.2.2. North America Sickle Cell Disease Market, 2018 - 2030 (USD Million)
    • 6.2.3. U.S.
      • 6.2.3.1. Key Country Dynamics
      • 6.2.3.2. Target Disease Prevalence
      • 6.2.3.3. Competitive Scenario
      • 6.2.3.4. Regulatory Framework
      • 6.2.3.5. U.S. Sickle Cell Disease Market, 2018 - 2030 (USD Million)
    • 6.2.4. Canada
      • 6.2.4.1. Key Country Dynamics
      • 6.2.4.2. Target Disease Prevalence
      • 6.2.4.3. Competitive Scenario
      • 6.2.4.4. Regulatory Framework
      • 6.2.4.5. Canada Sickle Cell Disease Market, 2018 - 2030 (USD Million)
  • 6.3. Europe
    • 6.3.1. SWOT Analysis
    • 6.3.2. Europe Sickle Cell Disease Market, 2018 - 2030 (USD Million)
    • 6.3.3. UK
      • 6.3.3.1. Key Country Dynamics
      • 6.3.3.2. Target Disease Prevalence
      • 6.3.3.3. Competitive Scenario
      • 6.3.3.4. Regulatory Framework
      • 6.3.3.5. UK Sickle Cell Disease Market, 2018 - 2030 (USD Million)
    • 6.3.4. Germany
      • 6.3.4.1. Key Country Dynamics
      • 6.3.4.2. Target Disease Prevalence
      • 6.3.4.3. Competitive Scenario
      • 6.3.4.4. Regulatory Framework
      • 6.3.4.5. Germany Sickle Cell Disease Market, 2018 - 2030 (USD Million)
    • 6.3.5. France
      • 6.3.5.1. Key Country Dynamics
      • 6.3.5.2. Target Disease Prevalence
      • 6.3.5.3. Competitive Scenario
      • 6.3.5.4. Regulatory Framework
      • 6.3.5.5. France Sickle Cell Disease Market, 2018 - 2030 (USD Million)
    • 6.3.6. Italy
      • 6.3.6.1. Key Country Dynamics
      • 6.3.6.2. Target Disease Prevalence
      • 6.3.6.3. Competitive Scenario
      • 6.3.6.4. Regulatory Framework
      • 6.3.6.5. Italy Sickle Cell Disease Market, 2018 - 2030 (USD Million)
    • 6.3.7. Spain
      • 6.3.7.1. Key Country Dynamics
      • 6.3.7.2. Target Disease Prevalence
      • 6.3.7.3. Competitive Scenario
      • 6.3.7.4. Regulatory Framework
      • 6.3.7.5. Spain Sickle Cell Disease Market, 2018 - 2030 (USD Million)
    • 6.3.8. Denmark
      • 6.3.8.1. Key Country Dynamics
      • 6.3.8.2. Target Disease Prevalence
      • 6.3.8.3. Competitive Scenario
      • 6.3.8.4. Regulatory Framework
      • 6.3.8.5. Denmark Sickle Cell Disease Market, 2018 - 2030 (USD Million)
    • 6.3.9. Sweden
      • 6.3.9.1. Key Country Dynamics
      • 6.3.9.2. Target Disease Prevalence
      • 6.3.9.3. Competitive Scenario
      • 6.3.9.4. Regulatory Framework
      • 6.3.9.5. Sweden Sickle Cell Disease Market, 2018 - 2030 (USD Million)
    • 6.3.10. Norway
      • 6.3.10.1.Key Country Dynamics
      • 6.3.10.2.Target Disease Prevalence
      • 6.3.10.3.Competitive Scenario
      • 6.3.10.4.Regulatory Framework
      • 6.3.10.5.Norway Sickle Cell Disease Market, 2018 - 2030 (USD Million)
  • 6.4. Asia Pacific
    • 6.4.1. SWOT Analysis
    • 6.4.2. Asia Pacific Sickle Cell Disease Market, 2018 - 2030 (USD Million)
    • 6.4.3. Japan
      • 6.4.3.1. Key Country Dynamics
      • 6.4.3.2. Target Disease Prevalence
      • 6.4.3.3. Competitive Scenario
      • 6.4.3.4. Regulatory Framework
      • 6.4.3.5. Japan Sickle Cell Disease Market, 2018 - 2030 (USD Million)
    • 6.4.4. China
      • 6.4.4.1. Key Country Dynamics
      • 6.4.4.2. Target Disease Prevalence
      • 6.4.4.3. Competitive Scenario
      • 6.4.4.4. Regulatory Framework
      • 6.4.4.5. China Sickle Cell Disease Market, 2018 - 2030 (USD Million)
    • 6.4.5. India
      • 6.4.5.1. Key Country Dynamics
      • 6.4.5.2. Target Disease Prevalence
      • 6.4.5.3. Competitive Scenario
      • 6.4.5.4. Regulatory Framework
      • 6.4.5.5. India Sickle Cell Disease Market, 2018 - 2030 (USD Million)
    • 6.4.6. Australia
      • 6.4.6.1. Key Country Dynamics
      • 6.4.6.2. Target Disease Prevalence
      • 6.4.6.3. Competitive Scenario
      • 6.4.6.4. Regulatory Framework
      • 6.4.6.5. Australia Sickle Cell Disease Market, 2018 - 2030 (USD Million)
    • 6.4.7. Thailand
      • 6.4.7.1. Key Country Dynamics
      • 6.4.7.2. Target Disease Prevalence
      • 6.4.7.3. Competitive Scenario
      • 6.4.7.4. Regulatory Framework
      • 6.4.7.5. Thailand Sickle Cell Disease Market, 2018 - 2030 (USD Million)
    • 6.4.8. South Korea
      • 6.4.8.1. Key Country Dynamics
      • 6.4.8.2. Target Disease Prevalence
      • 6.4.8.3. Competitive Scenario
      • 6.4.8.4. Regulatory Framework
      • 6.4.8.5. South Korea Sickle Cell Disease Market, 2018 - 2030 (USD Million)
  • 6.5. Latin America
    • 6.5.1. SWOT Analysis
    • 6.5.2. Latin America Sickle Cell Disease Market, 2018 - 2030 (USD Million)
    • 6.5.3. Brazil
      • 6.5.3.1. Key Country Dynamics
      • 6.5.3.2. Target Disease Prevalence
      • 6.5.3.3. Competitive Scenario
      • 6.5.3.4. Regulatory Framework
      • 6.5.3.5. Brazil Sickle Cell Disease Market, 2018 - 2030 (USD Million)
    • 6.5.4. Mexico
      • 6.5.4.1. Key Country Dynamics
      • 6.5.4.2. Target Disease Prevalence
      • 6.5.4.3. Competitive Scenario
      • 6.5.4.4. Regulatory Framework
      • 6.5.4.5. Mexico Sickle Cell Disease Market, 2018 - 2030 (USD Million)
    • 6.5.5. Argentina
      • 6.5.5.1. Key Country Dynamics
      • 6.5.5.2. Target Disease Prevalence
      • 6.5.5.3. Competitive Scenario
      • 6.5.5.4. Regulatory Framework
      • 6.5.5.5. Argentina Sickle Cell Disease Market, 2018 - 2030 (USD Million)
  • 6.6. MEA
    • 6.6.1. SWOT Analysis
    • 6.6.2. MEA Sickle Cell Disease Market, 2018 - 2030 (USD Million)
    • 6.6.3. South Africa
      • 6.6.3.1. Key Country Dynamics
      • 6.6.3.2. Target Disease Prevalence
      • 6.6.3.3. Competitive Scenario
      • 6.6.3.4. Regulatory Framework
      • 6.6.3.5. South Africa Sickle Cell Disease Market, 2018 - 2030 (USD Million)
    • 6.6.4. Saudi Arabia
      • 6.6.4.1. Key Country Dynamics
      • 6.6.4.2. Target Disease Prevalence
      • 6.6.4.3. Competitive Scenario
      • 6.6.4.4. Regulatory Framework
      • 6.6.4.5. Saudi Arabia Sickle Cell Disease Market, 2018 - 2030 (USD Million)
    • 6.6.5. UAE
      • 6.6.5.1. Key Country Dynamics
      • 6.6.5.2. Target Disease Prevalence
      • 6.6.5.3. Competitive Scenario
      • 6.6.5.4. Regulatory Framework
      • 6.6.5.5. UAE Sickle Cell Disease Market, 2018 - 2030 (USD Million)
    • 6.6.6. Kuwait
      • 6.6.6.1. Key Country Dynamics
      • 6.6.6.2. Target Disease Prevalence
      • 6.6.6.3. Competitive Scenario
      • 6.6.6.4. Regulatory Framework
      • 6.6.6.5. Kuwait Sickle Cell Disease Market, 2018 - 2030 (USD Million)

Chapter 7 Competitive Analysis

  • 7.1 Company Categorization
  • 7.2 Strategy Mapping
    • 7.2.1 New product launch
    • 7.2.2 Partnerships
    • 7.2.3 Acquisition
    • 7.2.4 Collaboration
  • 7.3 Company Profiles
    • 7.3.1 Novartis AG
      • 7.3.1.1 Company overview
      • 7.3.1.2 Financial performance
      • 7.3.1.3 Product benchmarking
      • 7.3.1.4 Strategic initiatives
    • 7.3.2 Pfizer Inc.
      • 7.3.2.1 Company overview
      • 7.3.2.2 Financial performance
      • 7.3.2.3 Product benchmarking
      • 7.3.2.4 Strategic initiatives
    • 7.3.3 bluebird bio, Inc.
      • 7.3.3.1 Company overview
      • 7.3.3.2 Financial performance
      • 7.3.3.3 Product benchmarking
      • 7.3.3.4 Strategic initiatives
    • 7.3.4 GlycoMimetics
      • 7.3.4.1 Company overview
      • 7.3.4.2 Financial performance
      • 7.3.4.3 Product benchmarking
      • 7.3.4.4 Strategic initiatives
    • 7.3.5 Emmaus Medical, Inc.
      • 7.3.5.1 Company overview
      • 7.3.5.2 Financial performance
      • 7.3.5.3 Product benchmarking
      • 7.3.5.4 Strategic initiatives
    • 7.3.6 Bristol-Myers Squibb Company
      • 7.3.6.1 Company overview
      • 7.3.6.2 Financial performance
      • 7.3.6.3 Product benchmarking
      • 7.3.6.4 Strategic initiatives
    • 7.3.7 CRISPR Therapeutics
      • 7.3.7.1 Company overview
      • 7.3.7.2 Financial performance
      • 7.3.7.3 Product benchmarking
      • 7.3.7.4 Strategic initiatives
    • 7.3.8 Graphite Bio, Inc.
      • 7.3.8.1 Company overview
      • 7.3.8.2 Financial performance
      • 7.3.8.3 Product benchmarking
      • 7.3.8.4 Strategic initiatives

List of Tables

  • Table 1 North America sickle cell disease treatment market, by country, 2018 - 2030 (USD Million)
  • Table 2 North America sickle cell disease treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 3 North America Sickle Cell Disease Treatment Market, by End-use, 2018 - 2030 (USD Million)
  • Table 4 U.S. sickle cell disease treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 5 U.S. Sickle Cell Disease Treatment Market, by End-use, 2018 - 2030 (USD Million)
  • Table 6 Canada sickle cell disease treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 7 Canada Sickle Cell Disease Treatment Market, by End-use, 2018 - 2030 (USD Million)
  • Table 8 Europe sickle cell disease treatment market, by country, 2018 - 2030 (USD Million)
  • Table 9 Europe sickle cell disease treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 10 Europe Sickle Cell Disease Treatment Market, by End-use, 2018 - 2030 (USD Million)
  • Table 11 UK sickle cell disease treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 12 UK Sickle Cell Disease Treatment Market, by End-use, 2018 - 2030 (USD Million)
  • Table 13 Germany sickle cell disease treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 14 Germany Sickle Cell Disease Treatment Market, by End-use, 2018 - 2030 (USD Million)
  • Table 15 France sickle cell disease treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 16 France Sickle Cell Disease Treatment Market, by End-use, 2018 - 2030 (USD Million)
  • Table 17 Italy sickle cell disease treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 18 Italy Sickle Cell Disease Treatment Market, by End-use, 2018 - 2030 (USD Million)
  • Table 19 Spain sickle cell disease treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 20 Spain Sickle Cell Disease Treatment Market, by End-use, 2018 - 2030 (USD Million)
  • Table 21 Denmark sickle cell disease treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 22 Denmark Sickle Cell Disease Treatment Market, by End-use, 2018 - 2030 (USD Million)
  • Table 23 Sweden sickle cell disease treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 24 Sweden Sickle Cell Disease Treatment Market, by End-use, 2018 - 2030 (USD Million)
  • Table 25 Norway sickle cell disease treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 26 Norway Sickle Cell Disease Treatment Market, by End-use, 2018 - 2030 (USD Million)
  • Table 27 Asia Pacific sickle cell disease treatment market, by country, 2018 - 2030 (USD Million)
  • Table 28 Asia Pacific sickle cell disease treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 29 Asia Pacific Sickle Cell Disease Treatment Market, by End-use, 2018 - 2030 (USD Million)
  • Table 30 Japan sickle cell disease treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 31 Japan Sickle Cell Disease Treatment Market, by End-use, 2018 - 2030 (USD Million)
  • Table 32 China sickle cell disease treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 33 China Sickle Cell Disease Treatment Market, by End-use, 2018 - 2030 (USD Million)
  • Table 34 India sickle cell disease treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 35 India Sickle Cell Disease Treatment Market, by End-use, 2018 - 2030 (USD Million)
  • Table 36 Australia sickle cell disease treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 37 Australia Sickle Cell Disease Treatment Market, by End-use, 2018 - 2030 (USD Million)
  • Table 38 South Korea sickle cell disease treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 39 South Korea Sickle Cell Disease Treatment Market, by End-use, 2018 - 2030 (USD Million)
  • Table 40 Thailand sickle cell disease treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 41 Thailand Sickle Cell Disease Treatment Market, by End-use, 2018 - 2030 (USD Million)
  • Table 42 Latin America sickle cell disease treatment market, by country, 2018 - 2030 (USD Million)
  • Table 43 Latin America sickle cell disease treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 44 Latin America Sickle Cell Disease Treatment Market, by End-use, 2018 - 2030 (USD Million)
  • Table 45 Brazil sickle cell disease treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 46 Brazil Sickle Cell Disease Treatment Market, by End-use, 2018 - 2030 (USD Million)
  • Table 47 Mexico sickle cell disease treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 48 Mexico Sickle Cell Disease Treatment Market, by End-use, 2018 - 2030 (USD Million)
  • Table 49 Argentina sickle cell disease treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 50 Argentina Sickle Cell Disease Treatment Market, by End-use, 2018 - 2030 (USD Million)
  • Table 51 MEA sickle cell disease treatment market, by country, 2018 - 2030 (USD Million)
  • Table 52 MEA sickle cell disease treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 53 MEA Sickle Cell Disease Treatment Market, by End-use, 2018 - 2030 (USD Million)
  • Table 54 South Africa sickle cell disease treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 55 South Africa Sickle Cell Disease Treatment Market, by End-use, 2018 - 2030 (USD Million)
  • Table 56 Saudi Arabia sickle cell disease treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 57 Saudi Arabia Sickle Cell Disease Treatment Market, by End-use, 2018 - 2030 (USD Million)
  • Table 58 UAE sickle cell disease treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 59 UAE Sickle Cell Disease Treatment Market, by End-use, 2018 - 2030 (USD Million)
  • Table 60 Kuwait sickle cell disease treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 61 Kuwait Sickle Cell Disease Treatment Market, by End-use, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Information procurement
  • Fig. 3 Value chain-based sizing & forecasting
  • Fig. 4 QFD modeling for market share assessment
  • Fig. 5 Market summary, 2023
  • Fig. 6 Market trends & outlook
  • Fig. 7 Market segmentation & scope
  • Fig. 8 Market driver relevance analysis (Current & future impact)
  • Fig. 9 Market restrain relevance analysis (Current & future impact)
  • Fig. 10 SWOT analysis, by factor (political & legal, economic and technological)
  • Fig. 11 Porter's Five Forces Analysis
  • Fig. 12 Sickle cell disease treatment market treatment outlook key takeaways
  • Fig. 13 Sickle cell disease treatment market: Treatment movement analysis
  • Fig. 14 Global bone marrow transplant market, 2018 - 2030 (USD Million)
  • Fig. 15 Global blood transfusion market, 2018 - 2030 (USD Million)
  • Fig. 16 Global pharmacotherapy market, 2018 - 2030 (USD Million)
  • Fig. 17 Sickle cell disease treatment market End-use outlook key takeaways
  • Fig. 18 Sickle cell disease treatment market: End-use movement analysis
  • Fig. 19 Global Hospitals market, 2018 - 2030 (USD Million)
  • Fig. 20 Global Specialty Clinics market, 2018 - 2030 (USD Million)
  • Fig. 21 Global other market, 2018 - 2030 (USD Million)
  • Fig. 22 Regional marketplace: Key takeaways
  • Fig. 23 Regional marketplace: Key takeaways
  • Fig. 24 North America sickle cell disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 25 Key country dynamics
  • Fig. 26 U.S. sickle cell disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 27 Key country dynamics
  • Fig. 28 Canada sickle cell disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 29 Europe sickle cell disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 30 Key country dynamics
  • Fig. 31 UK sickle cell disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 32 Key country dynamics
  • Fig. 33 Germany sickle cell disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 34 Key country dynamics
  • Fig. 35 France sickle cell disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 36 Key country dynamics
  • Fig. 37 Spain sickle cell disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 38 Key country dynamics
  • Fig. 39 Italy sickle cell disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 40 Key country dynamics
  • Fig. 41 Denmark sickle cell disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 42 Key country dynamics
  • Fig. 43 Sweden sickle cell disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 44 Key country dynamics
  • Fig. 45 Norway sickle cell disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 46 Rest of Europe sickle cell disease treatment market estimates and forecasts, 2018 - 2030 (USD, Million)
  • Fig. 47 Asia Pacific sickle cell disease treatment market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 48 Key country dynamics
  • Fig. 49 Japan sickle cell disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 50 Key country dynamics
  • Fig. 51 China sickle cell disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 52 Key country dynamics
  • Fig. 53 India sickle cell disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 54 Key country dynamics
  • Fig. 55 South Korea sickle cell disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 56 South Korea reimbursement scenario
  • Fig. 57 Key country dynamics
  • Fig. 58 Australia sickle cell disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 59 Key country dynamics
  • Fig. 60 Thailand sickle cell disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 61 Rest of Asia Pacific sickle cell disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 62 Latin America sickle cell disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 63 Key country dynamics
  • Fig. 64 Brazil sickle cell disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 65 Key country dynamics
  • Fig. 66 Mexico sickle cell disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 67 Key country dynamics
  • Fig. 68 Argentina sickle cell disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 69 Rest of Latin America sickle cell disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 70 MEA sickle cell disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 71 Key country dynamics
  • Fig. 72 South Africa sickle cell disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 73 Key country dynamics
  • Fig. 74 Saudi Arabia sickle cell disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 75 Key country dynamics
  • Fig. 76 UAE sickle cell disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 77 Key country dynamics
  • Fig. 78 Kuwait sickle cell disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 79 Rest of MEA sickle cell disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 80 Key company categorization
  • Fig. 81 Company categorization
  • Fig. 82 Company market share analysis, 2023
  • Fig. 83 Strategic framework